Your browser doesn't support javascript.
loading
A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.
Emran, Abdullah Al; Tseng, Hsin-Yi; Gunatilake, Dilini; Cook, Stuart J; Ahmed, Farzana; Wang, Shudong; Hersey, Peter; Gallagher, Stuart J; Tiffen, Jessamy C.
Afiliación
  • Emran AA; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Tseng HY; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Gunatilake D; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Cook SJ; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Ahmed F; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Wang S; Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, Australia.
  • Hersey P; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Gallagher SJ; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
  • Tiffen JC; Melanoma Immunology and Oncology Program, The Centenary Institute, Royal Prince Alfred Hospital, The University of Sydney, Camperdown, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia. Electronic address: j.tiffen@centenary.org.au.
J Invest Dermatol ; 141(9): 2238-2249.e12, 2021 09.
Article en En | MEDLINE | ID: mdl-33781756
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinas / Neoplasias Cutáneas / Sulfonamidas / Receptores de Superficie Celular / Quinasa 9 Dependiente de la Ciclina / Melanoma / Proteínas del Tejido Nervioso / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: J Invest Dermatol Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinas / Neoplasias Cutáneas / Sulfonamidas / Receptores de Superficie Celular / Quinasa 9 Dependiente de la Ciclina / Melanoma / Proteínas del Tejido Nervioso / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: J Invest Dermatol Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos